Literature DB >> 25780037

Minimal sequence requirements for oligodeoxyribonucleotides activating human TLR9.

Jelka Pohar1, Alenka Kužnik Krajnik1, Roman Jerala2, Mojca Benčina2.   

Abstract

Synthetic oligodeoxyribonucleotides (ODNs) containing CpG (unmethylated deoxycytidylyl-deoxyguanosine dinucleotide) motifs activate endosomal TLR9. The nucleotide sequence, length, and dimerization properties of ODNs modulate their activation of TLR9. We performed a systematic investigation of the sequence motifs of B-class and C-class phosphodiester ODNs to identify the sequence properties that govern TLR9 activation. ODNs shorter than 21 nt and with the adenosine adjacent to the cytidine-guanosine (CG) dinucleotide motif led to a significant loss of the propensity to activate TLR9. The distance between the stimulatory CpG motifs within the ODN fine-tunes the activation of B cells. The minimal ODNs that activate human TLR9 comprise 2 CG dinucleotides separated by 6-10 nt, where the first CpG motif is preceded by the 5'-thymidine and the elongated poly-thymidine tail at the 3' end of the ODN. The minimal sequence provides insight into the molecular mechanism of TLR9 ligand recognition. On the basis of sequence requirements, we conclude that two binding sites with different affinities for CG are formed in the human TLR9 dimer, with a very stringent binding site interacting with the 5' CpG motif.
Copyright © 2015 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25780037     DOI: 10.4049/jimmunol.1402755

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  17 in total

Review 1.  Structural aspects of nucleic acid-sensing Toll-like receptors.

Authors:  Umeharu Ohto; Toshiyuki Shimizu
Journal:  Biophys Rev       Date:  2016-02-12

2.  FcγRIIIa Signaling Modulates Endosomal TLR Responses in Human CD4+ T Cells.

Authors:  Anil K Chauhan
Journal:  J Immunol       Date:  2017-05-12       Impact factor: 5.422

Review 3.  Innate Sensing of DNA Virus Genomes.

Authors:  Zhe Ma; Guoxin Ni; Blossom Damania
Journal:  Annu Rev Virol       Date:  2018-09-29       Impact factor: 10.431

Review 4.  The Role of Nucleic Acid Sensing in Controlling Microbial and Autoimmune Disorders.

Authors:  Keesha M Matz; R Marena Guzman; Alan G Goodman
Journal:  Int Rev Cell Mol Biol       Date:  2018-09-25       Impact factor: 6.813

5.  Short-Fragment DNA Residue from Vaccine Purification Processes Promotes Immune Response to the New Inactivated EV71 Vaccine by Upregulating TLR9 mRNA.

Authors:  Jie Shao; Fan Gao; Hui-Juan Lin; Qun-Ying Mao; Pan Chen; Xing Wu; Xin Yao; Wei Kong; Zheng-Lun Liang
Journal:  PLoS One       Date:  2016-04-15       Impact factor: 3.240

6.  Distinctive Recognition of Flagellin by Human and Mouse Toll-Like Receptor 5.

Authors:  Vida Forstnerič; Karolina Ivičak-Kocjan; Ajasja Ljubetič; Roman Jerala; Mojca Benčina
Journal:  PLoS One       Date:  2016-07-08       Impact factor: 3.240

7.  Phosphodiester backbone of the CpG motif within immunostimulatory oligodeoxynucleotides augments activation of Toll-like receptor 9.

Authors:  Jelka Pohar; Duško Lainšček; Ana Kunšek; Miša-Mojca Cajnko; Roman Jerala; Mojca Benčina
Journal:  Sci Rep       Date:  2017-11-06       Impact factor: 4.379

8.  Short single-stranded DNA degradation products augment the activation of Toll-like receptor 9.

Authors:  Jelka Pohar; Duško Lainšček; Karolina Ivičak-Kocjan; Miša-Mojca Cajnko; Roman Jerala; Mojca Benčina
Journal:  Nat Commun       Date:  2017-05-22       Impact factor: 14.919

9.  The proprotein convertase PC1/3 regulates TLR9 trafficking and the associated signaling pathways.

Authors:  M Duhamel; F Rodet; A N Murgoci; R Desjardins; H Gagnon; M Wisztorski; I Fournier; R Day; M Salzet
Journal:  Sci Rep       Date:  2016-01-18       Impact factor: 4.379

Review 10.  Biodegradable Polymeric Nanoparticles-Based Vaccine Adjuvants for Lymph Nodes Targeting.

Authors:  Alice Gutjahr; Capucine Phelip; Anne-Line Coolen; Claire Monge; Anne-Sophie Boisgard; Stéphane Paul; Bernard Verrier
Journal:  Vaccines (Basel)       Date:  2016-10-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.